Agenda

Learning Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approved since July 2018
• Emphasize clinical pearls/best practice for managing patients clinically within the disease process

Learning Objectives:

• Current update asto role of copay accumulator in patient benefit management
• Look at best practices in relation to utilization of third-party financial support, including Foudnation Programs, co-pay cards, and Patient Assitance Programs
• Discuss cost control and management, from patient through payor

Learning Objectives:

• Analyze proposed areas of reform, including Medicare Part D Pharmacy DIR, Medicare Part D Rebates, and Medicare Part B
• Outline the effects on Medicare Part D Protected Classes
• Assess the Medicare 340B Program, including legal challenges and impacts

Learning Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approved since July 2018
• Emphasize clincal pearls / best practice for managing patients clinically within the disease process

Learning Objectives:

• Open discussion surroudning key data elements shared across the specialty pharmacy industry
• Provide insight as to elements of standardization attempted by key parties involved
• Address challenges to further standardization of data, and highlight ways to overcome

Learning Objectives:

• Focus on best case relationships between specialty pharmacies and payors, including clinical programs
• Highlight approaches to specialty pharmacy contracting, key takeaways for capabilities, and cost management 
• Review formulary management tactics from high-performing relationships and ways to implement industry wide 

Learning Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approve since July 2018
• Emphasizeclinical pearls / best practice for managing patientsclinically within the disease process

Learning Objectives:

• Review Policy Priorities and Position Statements supported by NASP
• Outline Congressional and Regulatory Action
•  Illustrate the role of the NASP Political Action Committee, along with other NASP Grassroots efforts

Learning Objectives:

• Highlight key pharmacogenomics trends and case examples of its use in speciatly pharmacy practice
• What does the future hold for specialty pharmacy and artificial intelligence?
• Technology and specialty pharmacy seem like a perfect fit - how can that model adapt to benefit all stakeholders

Learning Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approved since July 2018
• Emphasize clinical pearls / best practice formanaging patientsclinically within the disease process

Learning Objectives:

• Discuss referral management process and steps to receipt of referral
• Highlight points of confusion related to intake period, and how to surmount challenges
  • Provide best practices in SP-prescriber relationships to improve conversations related to decreasing time-to-fill

Learning Objectives:

• Review regulations affecting pharmacy operations, including prescription drug management programs,non-resident licensure, and accreditation
• Identify key characteristics to gain efficiency in compliance with each
  • Discuss best practices demonstrate compliance with each aspect

Learning Objectives:

• Examine current standards of care within this disease area
• Identify new agents that had been approved over the last 12 months
• Examine clinical pearls and best practices for clinically managing patients within the disease process

Learning Objectives:

• Review updates to prescription handling and cold chain management standards
• Discuss best practices to comply by the Drug Supply Chain Security Act (DSCSA)
• Describe advancements in packaging, returns handling, and other areas of the fulfillment process

Learning Objectives:

• Review public case examples of value-based care in action
• Analyze key findings from specialty pharmacy involvement in outcomes management and true value-based care
• Identify areas for specialty pharmacy growth to aid in expansion of value-based care

Learning Objectives:

• Highlight current standards of care withint this disease state
• Review new agents that had been approved since July 2018
• Emphsize clinical pearls / best practice for managing patients clinically within the disease process

Learning Objectives:

• Open discussion surrounding key data elements shared across the specialty pharmacy industry
• Provide insight as to elements of standardization attempted by key parties involved
  • Address challenges to further standardization of data and highlight ways to overcome

Learning Objectives:

• Highlight SPC Board partnership / current state of CSP Exam & industry acceptance
• Overview of SP Satisfaction Survey results focused on multiple stakeholder perspectives
  • Detail sales training & CE initiatives forthcoming from NASP

Meeting Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approved since July 2018
• Emphasize clinical pearls / best practice for managing patients clinically within the disease process

Learning Objectives:

• Current update as to role of copay accumulator in patient beneift management 
• Look at best practices in relation to utilization of third-party financial support, including Foundation Programs, co-pay cards, and Patient Assistance Programs
• Discuss cost control and management, from patient through payor

Learning Objectives:

• Focus on best case relationships between specialty pharmacies and manufacturers, including clinical programs
• Highlight approaches to speciatly pharmacy contracting,  key takeaways for capabilities and cost management 
• Review case examples of high-performing limited distribution models and the pros/cons across the supply chain

Learning Objectives:

• Highlight current standards of care within this disease state
• Review new agents that had been approved since July 2018
• Emphasize clinical pearls / best practice for managing patients clinically within the disease process

Learning Objectives:

• Provide an overview of the FDA's Biosimilar Action Plan
• Discuss status of plan, and changes that have occurred since initial presentation
• Review current slate of biosimilar medications, and the Action Plan’s proposed impact on growth of this industry segment

Learning Objectives:

• Evaluate the landscape of health system specialty pharmacy growth
• Propose models of efficiency related to health system, integrated delivery, or hybrid models of care
• Highlight practice pearls for managing transition of care from diagnosis through outpatient journey as well as foundational inquiries about beginning the process of building a SP

Learning Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approved since July 2018
• Emphasize clinical pearls/best practice for managing patients clinically within the disease process

Learning Objectives:

• Review multistakeholder considerations for rare disease therapy management, including accreditors, specialty pharmacies, payors, and geneticists
• Determine the impact of rare disease therapies via case studies on each of the associated stakeholder
• Discuss best practices needed for handling and management of rare disease therapies within the specialty pharmacy continuum

Learning Objectives:

• Highlight key pharmacogenomics trends and case examples of its use in specialty pharmacy practice
• What does the future hold for specialty pharmacy and artificial intelligence?
• Technology and specialty pharmacy seem like a perfect fit – how can that model adapt to benefit all stakeholders

Learning Objectives:

• Define the role technology plays in speed to therapy
• Identify the challenges in specialty prescribing
• Articulate the outcomes seen from utilization of technology solutions in specialty prescribing

Learning Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approved since July 2018
• Emphasize clinical pearls/best practice for managing patients clinically within the disease process

Meeting Objectives:

• Review current state of DIR on the specialty pharmacy industry
• Identify changes that have occurred related to legislation and management over the last several months
• Discuss best practices for handling, management of, and advocacy related to the future of DIR

Learning Objectives:

• Highlight current standards of care within this disease area
• Review new agents that had been approved since July 2018
  • Emphasize clincal pearls / best practice for managing patients clinically within the disease process

Learning Objectives:

• Review Medication Possession Ratio and Proportion of Days Covered as indicator of patient adherence / non-adherence
• Discuss other markers for patient adherence
  • Case study of best practices related to driving patient adherence through intervention and engagement

Learning Objectives:

• Review public case examples of value-based care in action
• Take away key learnings from specialty pharmacy involvement in outcomes mangement and true value-based care
  • Identify key areas for specialty pharmcy growth to aid in this area

Learning Objectives:

• Highlight current standards of care within this disease area
• REview new agents that had been approved since July 2018
  • Emphasize clinical pearls / best practice for managing patients clinically within the disease process

Learning Objectives:

• Review regulations affecting pharmacy operations, including prescription drug management programs, non-resident licensure, and accreditation
• Identify key characteristics to gain efficiency in compliance with each
  • Discuss best practices demonstrate complianace with each aspect

Learning Objectives:

• Distinguish between core and enhanced specialty pharmacy offerings
• Compare different service models, including internal or external HUB service providers
  • Illustrate successful enhanced service programs and the value afforded to the patient journey, including staffing models with nursing